Navigation Links
Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval
Date:1/31/2011

ually.(i) Worldwide, more than 180,000 people are living with multiple myeloma and approximately 86,000 new cases are diagnosed annually.(ii)

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a selective proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma in various settings and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Forward Looking Statements

This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws.  These forward-looking statements include without limitation, statements regarding the progress and results of the clinical development, safety, regulatory processes, including FDA review, and commercialization efforts or commercial potential of carfilzomib.  These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related to the development, regulatory approval and commercialization of pharmaceutical products. &#
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... April 21, 2015 YourEncore, an ... life sciences, consumer products and food sciences industries ... the Alliance for Clinical Research Excellence and Safety ... for conducting clinical research, have partnered to speed ... , YourEncore brings to ACRES experts with ...
(Date:4/20/2015)... Champaign, IL (PRWEB) April 20, 2015 ... establishment of its 12th clinical research site: PMG Research ... has assumed operation of the clinical research department at ... footprint outside the Southeast to a second region within ... 150 multi-specialty physician practice enhances PMG’s access to an ...
(Date:4/20/2015)... Calif. , April 20, 2015 PointCross ... Pvt. Ltd. to provide an integrated Big Data and ... all biomarkers collected in the context of clinical trials ... of precise or multi-targeted drug candidates, stratified patient selection ... disease progression free survival. Highlighting the ...
(Date:4/20/2015)... 20, 2015 - Development of ... Using the VOLVOX Platform - To be Presented on ... -  Supramolecular Assembly of Antibody-drug Conjugates Using an anti-HER2 ... on Sunday, Apr 19, 1:00 PM EST ... program, today announced that the company,s novel computational platform ...
Breaking Biology Technology:YourEncore and ACRES Partner to Drive Innovation in Clinical Research 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 3PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 2PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 3PointCross Life Sciences and InterpretOmics partner for Clinical and Genomic Biomarker Management for Drug Development 2Invictus Oncology Announces Two Posters to be Presented Describing its Platform Technology on Supramolecular Therapeutics at the American Association for Cancer Research Annual Meeting, 2015 2
... 2011 HumanTouch, LLC today announced that they were ... Contractors list.   The Fast 50 list ... market conditions and build a sustainable business.  As Washington ... Fast 50 range from resellers to consultants and IT ...
... Resonetics introduces the RapidX250 laser micromachining system, developed ... MEMs and medical devices in a rapid prototype ... devices are fabricated by traditional semiconductor lithography but ... uses a multi-wavelength excimer laser (193nm and 248nm) ...
... Md., Aug. 3, 2011 Neuralstem, Inc. (NYSE Amex: ... Department of Defense (DOD) contract to develop its human ... brain tumors. The research contract, entitled "Research to Treat ... carried out in collaboration with Principal Investigator John Zhang, ...
Cached Biology Technology:RapidX250 Rapid Prototype Tool for Micro Fabrication of Microfluidics, MEMs and Medical Devices 2Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 2Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 3
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... for new antibiotics: A new research published in the July ... http://www.fasebj.org ) explains for the first time how honey kills ... that they add to the honey, called defensin-1, which could ... and to develop new drugs that could combat antibiotic-resistant infections. ...
... WEST LAFAYETTE, Ind. - Fast-food restaurants can supersize French ... to supersize a type of apple. Peter Hirst, a ... in some Gala apple trees causes some apples to grow ... reported in the current issue of the Journal of ...
... A drug used to treat rheumatoid arthritis also reduces ... lab research and preliminary findings from a clinical trial of ... clinical study to refine the drug anakinra,s use as an ... Nancy Rothwell will summarise her team,s latest research into both ...
Cached Biology News:Honey as an antibiotic: Scientists identify a secret ingredient in honey that kills bacteria 2Apples grow larger when cells don't divide, study shows 2New hope for victims of stroke 2
A cost-effective serum for general cell growth requirements. All serum is collected from calves aged 10 days old or less....
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Mfr ...
...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
Biology Products: